CompletedNot Applicable

A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Supplementation on Testosterone Levels in Healthy Men and Women Over an 18-week Period

United States34 participantsStarted 2025-01-30

Plain-language summary

The primary purpose of this study is to investigate the effects of geranylgeraniol (GG) supplementation on testosterone levels in middle-aged (40 to 65 years) healthy men and women. The research team hypothesizes that geranylgeraniol (GG) supplementation will enhance testosterone levels and improve self-reported health outcomes in a healthy population.

Who can participate

Age range40 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males and females between 40 to 65 years of age.
✓. Individuals with no significant history of inflammatory bowel disease (i.e. ulcerative colitis, Crohn's, Celiac, etc.), ulcers, liver and/or kidney disease or other any acute or chronic dis-ease.
✓. Ability to read and speak English
✓. Subject's agreement to voluntarily participate in the study
✓. Negative pregnancy test confirmed with serum HCG on initial baseline testing and baseline testing at the start of the crossover (at 10 weeks)

Exclusion criteria

✕. Males and females under 40 or over 65 years of age
✕. Previous (in the past 60 days) or current hormone replacement therapy
✕. Males and females with free testosterone levels over normal range
✕. History of hysterectomy, oophorectomy, or orchiectomy
✕. Current biotin supplementation \>3 mg per day one week prior to the start of the study
✕. Current or history of smoking
✕. CoQ10/Ubiquinol supplementation within the past 2 weeks
✕. Current use of hormone boosting supplements (i.e. fenugreek, shilajit, tongkat ali, ashwagandha) within the past 4 weeks

What they're measuring

Serum Total Testosterone (LC/MS-MS)

Timeframe: Baseline, 8 weeks, 10 weeks, and 18 weeks

Serum Free Testosterone (Direct)

Timeframe: Baseline, 8 weeks, 10 weeks, and 18 weeks

Trial details

NCT IDNCT06747624

SponsorDesigns for Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-19

View on ClinicalTrials.gov More Wellness trials